Nasal CDMO Edge Post-acquisition, Summit's intranasal formulation and cGMP manufacturing capabilities integrate with Kindeva to offer an end-to-end nasal drug-delivery CDMO solution from concept to commercial. This is attractive to biotech firms developing nasal sprays needing device integration, regulatory support, and manufacturing under one roof.

Acquisition Synergy The January 2024 acquisition broadens Kindeva's platform into intranasal delivery and creates cross-sell opportunities to existing clients while attracting new ones seeking drug-device combination products across nasal, pulmonary, injectable, and transdermal modalities.

Partnership Track Record Historic collaborations with Altimmune, Opiant, and Atossa demonstrate a proven track record in nasal delivery programs and complex formulations, signaling strong win potential with similar biotech and specialty pharma customers.

US Manufacturing Edge Based in Lexington, Kentucky with a cGMP facility, Summit provides U.S. manufacturing capabilities that can shorten lead times, support onshore supply strategies, and ease regulatory communications for domestic customers.

Growth Market Fit With mid-market revenue and a focused team, Summit fits mid-stage biotech and niche pharmaceutical programs that require specialized nasal device integration and scalable manufacturing, offering a cost-effective partner for growth without the scale burdens of larger CDMOs.